Manhattan Psychiatric Center
10
1
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
10.0%
1 terminated/withdrawn out of 10 trials
87.5%
+1.0% vs industry average
20%
2 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
A Virtual Reality Mindfulness Application for Aggression in Schizophrenia
Role: lead
Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder
Role: lead
Brain Activation Patterns in Schizophrenia After Computerized Cognitive Skills Training
Role: lead
Transcranial Direct-current Stimulation (tDCS) in Treatment Refractory Auditory Hallucinations
Role: lead
Cognitive Skills Training Using Computer for Patients With Severe Mental Illness
Role: collaborator
Relation of Catechol-O-methyltransferase (COMT) Genotype and Response to Cognitive Remediation Schizophrenia
Role: lead
High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder
Role: lead
Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder
Role: lead
Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder
Role: lead
Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness
Role: lead
All 10 trials loaded